Printer Friendly

GLAXO DOUBLES IT'S PARTICIPATION IN BIOCHEM PHARMA INC.

 LAVAL, Quebec, Jan. 18 /PRNewswire/ -- Today Glaxo Canada, subsidiary of Glaxo Holdings p.l.c. (U.K.) (NYSE: GLX), exercised its option to purchase approximately 3.9 million common shares of BioChem Pharma Inc., at an exercise price of $7.80 per share for a total of $30.3 million.
 The option was granted to Glaxo in January 1991, under the agreements between the companies covering the research and development of compounds discovered by BioChem for the treatment of viral diseases and cancer. This $30.3 million additional investment brings to around $72 million the equity and research investments by Glaxo in BioChem since 1990. Glaxo now holds around 17 percent of BioChem's common shares.
 "We believe this additional commitment from Glaxo is a very significant vote of confidence in our company" said Fracesco Bellini, President and CEO of BioChem Pharma Inc.
 BioChem Pharma is a pharmaceutical company dedicated to the research, development and commercialization of innovative products for the detection, prevention and treatment of human diseases. The company's shares are traded on the Montreal and Toronto stock exchanges (BCH) and on the NASDAQ stock market (BCHXF).
 -0- 1/18/93
 /CONTACT: Jean-Yves Duthel, vice-president - public relations of BioChem Pharma Inc., 514-681-1744; or Luc Beauregard or Michele Roy of National Public Relations Inc., 514-843-7171/
 (GLX)


CO: Glaxo Canada; Glaxo Holdings p.l.c. ST: Quebec IN: MTC SU:

AH -- NY018 -- 5810 01/18/93 10:14 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:237
Previous Article:MINERALS TECHNOLOGIES INC. TO BUILD PRECIPITATED CALCIUM CARBONATE FACILITY AT KINGSPORT, TENN., TO SUPPLY MEAD CORPORATION
Next Article:BAXTER INTERNATIONAL/APPLIED IMMUNE SCIENCES SIGN LICENSE FOR STEM CELL PATENTS
Topics:


Related Articles
3TC ACTIVE AGAINST HEPATITIS B VIRUS
BIOCHEM PHARMA WITHDRAWS INTERNATIONAL EQUITY OFFERING
BIOCHEM PHARMA: INTERIM DATA FROM PHASE I/II 3TC TRIALS PRESENTED AT MONTREAL HIV MEETING
LAMIVUDINE: EARLY PHASE II TRIAL RESULTS ENCOURAGING; LATE PHASE II TRIALS INITIATED
BIOCHEM PHARMA AND GLAXO EXTEND RESEARCH AGREEMENT
ONCOGENE SCIENCE, INC. ANNOUNCES SALE OF 500,000 SHARES OF COMMON STOCK TO BIOCHEM PHARMA INC.
BIOCHEM PHARMA ANNOUNCES REGULATORY SUBMISSION SEEKING APPROVAL OF LAMIVUDINE FOR HEPATITIS B IN THE UNITED STATES
ZEFFIX, FOR TREATMENT OF CHRONIC HEPATITIS B, APPROVED IN THE EUROPEAN UNION.
Biochem Parma Inc. - U.S. Patent Office Invalidates Emory University's Patent for 3TC/EPIVIR.
BioChem Pharma Inc./.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters